Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.69 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722464 | 0.93 | GAA (0.79) | GAAPLA2G1BATG4BALDH1A1KMT2A | |
| SCHEMBL15154933 | 0.87 | HPGD (0.68) | GAAPLA2G1BATG4BALDH1A1KMT2A | |
| SCHEMBL14236894 | 0.84 | GAA (0.68) | GAAPLA2G1BATG4BALDH1A1KMT2A | |
| SCHEMBL95624 | 0.84 | GAA (0.68) | GAAPLA2G1BATG4BALDH1A1KMT2A | |
| SCHEMBL3454938 | 0.84 | GAA (0.68) | GAAPLA2G1BATG4BALDH1A1KMT2A | |
| SCHEMBL5967832 | 0.84 | GAA (0.68) | GAAPLA2G1BATG4BALDH1A1KMT2A | |
| SCHEMBL3453484 | 0.84 | GAA (0.68) | GAAPLA2G1BATG4BALDH1A1KMT2A | |
| SCHEMBL14236778 | 0.84 | PLA2G1B (0.87) | GAAPLA2G1BATG4BALDH1A1KMT2A | |
| SCHEMBL14297352 | 0.83 | KMT2A (0.62) | ALDH1A1KMT2APKMHPGDMEN1 | |
| SCHEMBL17319245 | 0.83 | CRHBP (0.77) | ALDH1A1KMT2APKMHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206125-B2 | Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206125-B2 | Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20130203738-A1 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) | NAGOYA CITY UNIVERSITY (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130203738-A1 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) | NAGOYA CITY UNIVERSITY (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203738-A1 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) | RCOR1, MSI2, RCOR3 | GAA 4647/4885PLA2G1B 4678/4885ATG4B 4782/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | GAA 2220/4885PLA2G1B 1777/4885ATG4B 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.